Bovy P R, Collins J T, Olins G M, McMahon E G, Hutton W C
Searle R&D and MCR, Monsanto Life Sciences Research Center, St. Louis, Missouri 63198.
J Med Chem. 1991 Aug;34(8):2410-4. doi: 10.1021/jm00112a015.
The synthesis and in vitro activity of new nonpeptide angiotensin II antagonists is presented. Compared to previously reported biphenyl compounds, the new analogues 8 and 9 have reduced conformational freedom derived from steric hindrance. Methyl 4'-methyl-2',6'-dimethoxy[1,1'-biphenyl]-2-carboxylate 4 has been synthesized by a Von Pechmann condensation of orcinol with oxocyclohexane-2-carboxylate followed by dehydrogenation. This scheme provided the carbon skeleton of the biphenyl potentially substituted on the 2-, 2'-, 4'-, and 6'-positions. Elaboration of the subsituents led to a biphenyl derivative used to alkylate a 2-n-butyl-4-chloro-5-(hydroxymethyl)imidazole. After coupling with the imidazole two regioisomers were separated and identified by 1H NMR. NOESY experiments were useful to establish regiochemistry of the final products that have angiotensin II blocking activity. Their affinity for angiotensin II receptors was established in a binding assay experiment and in an isolated organ test. The presence of 2',6'-dimethoxy substituent on the biphenyl moiety of the antagonist was found to significantly decrease affinity for the receptor.
本文介绍了新型非肽类血管紧张素II拮抗剂的合成及其体外活性。与先前报道的联苯化合物相比,新类似物8和9由于空间位阻导致构象自由度降低。4'-甲基-2',6'-二甲氧基[1,1'-联苯]-2-羧酸甲酯4是通过邻苯二酚与氧代环己烷-2-羧酸酯的冯·佩希曼缩合反应,然后脱氢反应合成的。该方案提供了在2-、2'-、4'-和6'-位可能被取代的联苯碳骨架。对取代基的修饰得到一种联苯衍生物,用于烷基化2-正丁基-4-氯-5-(羟甲基)咪唑。与咪唑偶联后,分离出两种区域异构体,并通过1H NMR进行鉴定。NOESY实验有助于确定具有血管紧张素II阻断活性的最终产物的区域化学结构。它们对血管紧张素II受体的亲和力在结合试验和离体器官试验中得以确定。发现拮抗剂联苯部分上的2',6'-二甲氧基取代基会显著降低对受体的亲和力。